Alterations in Innate Immune Populations During Systemic Autoimmune Rheumatic Disease Development

Objectives Systemic autoimmune rheumatic diseases (SARD) are a group of chronic diseases characterized by the presence of antinuclear antibodies (ANAs).[1] However, ANAs cannot reliably be used as a diagnostic tool because a subset of healthy women are ANA+ (~20%) and the majority of these individuals will not progress to SARD.[2] Why some individuals progress while others remain asymptomatic is unknown. Our objective is to evaluate functional alterations in innate immune populations during SARD development. Methods Experiments have been completed to examine the composition of innate immune cells in PBMCs using CITE-Seq. Samples were used from 5 ANA- healthy controls, 11 ANA+ asymptomatic (5 progressors prior to progression, 6 non-progressors) and 8 early SARD patients. Five million freshly thawed PBMCs were depleted of T and B cells using α-CD3, -CD19 biotinylated antibodies with streptavidin coated magnetic beads. Purified innate immune cells were stained with a panel of oligo-conjugated antibodies for the identification of DC/monocyte populations. 9000 cells were sequenced at a depth of 50000 reads for gene expression and 5000 reads for CITE-Seq. Results Using both gene and surface protein expression, we identified 11 DC and monocyte populations (Figure 1A). Proportional analysis revealed an expansion of non-classical and activated non-classical monocytes in progressor and SARD patients (Figure 1B). SARD patients also exhibited higher proportions of cDC3s, VCAN+ monocytes and MME+ DCs than ANA+ individuals regardless of progression status suggesting a role for these cells in active disease (Figure 1B). Comparing ANA+ patients, classical, intermediate, and non-classical monocytes were expanded in progressors while cDC1s, cDC2s and pDCs were expanded in non-progressors (Figure 1B). Differential expression analysis indicated high expression of interferon stimulated genes in progressors and SARD patients, while non-progressors showed high expression of heat-shock proteins which have been shown to promote tolerogenic conditions. These differences in gene expression were observed across cell types, but intermediate monocytes are shown as representative cells due to their role in antigen presentation (Figure 1C). Several genes were differentially expressed between progressors and SARD, potentially highlighting distinct roles for genes in initiating and driving disease (Figure 1C). Further analysis will be done to examine pathways associated with these genes. Figure 1. A) UMAP of 11 annotated monocyte and DC clusters. B) Proportional analysis showing each cluster for control, non-progressor, progressor and SARD groups. Data was normalized to account for differences in cell counts per cluster and per patient sample. C) Heatmap showing differentially expressed genes in intermediate monocytes as a representative cell cluster. Similar trends were seen in the remaining cell types. Red arrows indicate genes of interest between progressor and SARD groups. Blue bars indicate differentially expressed genes between progressors and non-progressors. Conclusion Our data reveals differences in proportions and gene expression between progressors, non-progressors and SARD patients. Importantly, ANA+ progressors show expanded monocyte populations and functional differences compared to non-progressors even prior to progression. These results will allow us to investigate the immunological differences that may drive progression in SARD. [1.] Goldblatt F. Lancet 2013;382:797-808. [2.] Wither J. Arthritis Res Ther 2017;19:41.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.